Translating Basic Research Into Clinical Practice |

Immunotherapy of lung malignancies – from gene sequencing to novel therapies OPEN ACCESS

J. Chee, Ph.D; B.W.S.R. Robinson, M.D; R.A. Holt, Ph.D; J. Creaney, Ph.D
Author and Funding Information

Conflict of interest: JC, BWSR, RAH and JC declare no conflict of interest

1National Centre of Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia

2Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia

3BC Cancer Agency, Vancouver, British Columbia V5Z 1L3, Canada; Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada; Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, British Columbia V5A 1S6, Canada

Corresponding Author: School of Medicine and Pharmacology, M503, QQ Block, Sir Charles Gairdner Hospital, Nedlands, Perth, 6009, Australia.

Copyright 2016, . All Rights Reserved.

Chest. 2016. doi:10.1016/j.chest.2016.10.007
Text Size: A A A
Published online


Harnessing the immune system to fight cancer is an exciting advancement in lung cancer therapy. Anti-tumor immunity can be augmented by checkpoint blockade therapy, which removes the inhibition/brakes imposed on the immune system by the tumor. Checkpoint blockade therapy with anti-PD1/anti-PDL1 antibodies causes tumor regression in around 25% of lung cancer patients. In another approach, the immune system is forced or accelerated to attack the tumour, via augmentation of the anti-tumour response against mutations carried by each lung tumour. This latter approach has become feasible since the advent of next generation sequencing technology, which allows identification of the specific mutations that each individual lung tumor bears. Indeed lung cancers are now known to have high mutation rates, making them logical targets for mutation-directed immune therapies. We review how sequencing of lung cancer mutations leads to better understanding of how the immune system recognizes tumors, providing improved opportunities to track anti-tumor immunity, and ultimately the development of personalized vaccine strategies aimed at unleashing the host immune system to attack mutations in the tumor.

This article is only available in the PDF format. Download the PDF




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543